[18F]Fluciclovine in Post-treatment Glioblastoma ( Axumin )
Status:
Recruiting
Trial end date:
2023-01-01
Target enrollment:
Participant gender:
Summary
Subjects with histologically proven glioblastoma (GBM) who are suspected to have progression
and are candidates for a surgical resection according to standard of care may be eligible for
this study. Subjects may participate in this study if they are at least 18 years of age.
Positron emission tomography (PET/CT) imaging will be used to evaluate fluciclovine uptake at
sites of suspected progression before planned surgery. In addition, clinical brain MRI with
and without contrast will be used to evaluate the tumor pre-operatively. This is a
non-therapeutic trial in that imaging will not be used to direct treatment decisions.
Investigators anticipate enrolling up to 30 subjects who will undergo a clinical brain MRI
examination with and without contrast and a research 18F-Fluciclovine PET/CT scan of the
brain prior to surgery. They will also have a blood draw preoperatively to collect samples
for cfDNA analysis. PET/CT imaging sessions will include an injection of approximately 5 mCi
(range for most studies is anticipated to be 5 mCi +/- 20%) of 18F-Fluciclovine.